You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 4, 2024

Claims for Patent: 4,956,281

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,956,281

Title:	DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
Abstract:	Polypeptides that bind to CD2, the receptor on the surface of T-lymphocytes. Most preferably, the polypeptides bind to CD2 on the surface of T-lymphocytes and inhibit adhesion between T-lymphocytes and target cells. DNA sequences that code on expression in appropriate unicellular hosts for those polypeptides. Methods of making and using those polypeptides in therapy and diagnosis.
Inventor(s):	Wallner; Barbara P. (Cambridge, MA), Springer; Timothy A. (Newton, MA), Hession; Catherine (South Weymouth, MA), Tizard; Richard (Cambridge, MA), Mattaliano; Robert (Newton, MA), Dustin; Michael L. (Boston, MA)
Assignee:	Biogen, Inc. (Cambridge, MA) Dana Farber Cancer Institute, Inc. (Boston, MA)
Application Number:	07/057,615
Patent Claims:	1. A DNA sequence selected from the group consisting of: (a) the DNA sequence which codes for the LFA-3 polypeptide carried in phage .lambda.HT16; (b) DNA sequences which hybridize under conditions equivalent to about 20.degree. to 27.degree. C. below Tm and 1 M sodium chloride to the LFA-3 DNA sequence of (a) and which code on expression for a polypeptide that binds to CD2, the receptor on the surface of T-lymphocytes; and (c) DNA sequences which code on expression for a polypeptide that binds to CD2 which is coded for on expression by any of the foregoing DNA sequences. 2. The DNA sequence according to claim 1, wherein said DNA sequence (b) codes on expression for a polypeptide that binds to CD2 on the surface of T-lymphocytes and inhibits adhesion between T-lymphocytes and target cells. 3. The DNA sequence according to claim 2, wherein said polypeptide is soluble. 4. The DNA sequence according to claim 1, wherein said DNA sequence is selected from the group consisting of a DNA sequence of the formula N.sub.1-1047 of FIG. 3, a DNA sequence of the formula N.sub.17-766 of FIG. 3, a DNA sequence of the formula N.sub.101-766 of FIG. 3, a DNA sequence of the formula N.sub.101-611 -N.sub.716-766 of FIG. 3, a DNA sequence of the formula ATG-N.sub.101-766 of FIG. 3, a DNA sequence of the formula ATG-N.sub.101-661 -N.sub.716-766 of FIG. 3, and DNA sequences that code on expression for any of the above DNA sequences. 5. The DNA sequence according to claim 4, wherein said DNA sequence is selected from the group consisting of a DNA sequence of the formula N.sub.17-766 of FIG. 3, a DNA sequence of the formula ATG-N.sub.17-766 of FIG. 3, and DNA sequences that code on expression for any of the above DNA sequences. 6. A recombinant DNA molecule comprising a DNA sequence selected from the group consisting of the DNA sequences of claims 1 to 5, said DNA sequence being operatively linked to an expression control sequence in said recombinant DNA molecule. 7. The recombinant DNA molecule according to claim 6, wherein said expression control sequence is selected from the group consisting of the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage .lambda., the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase and the promoters of the yeast .alpha.-mating factors. 8. A unicellular host transformed with a recombinant DNA molecule selected from the group consisting of the recombinant DNA molecules of claim 6. 9. The host according to claim 8, wherein said host is selected from the group consisting of strains of E.coli, Pseudomonas, Bacillus, Streptomyces, fungi, animal cells, plant cells and human cells in tissue culture. 10. A method of producing a LFA-3 polypeptide comprising culturing a unicellular host transformed with a recombinant DNA molecule selected from the group consisting of the recombinant DNA molecules of claim 6 or 7.

Details for Patent 4,956,281

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036	01/30/2003	⤷ Try a Trial	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 4,956,281

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	8809820	⤷ Try a Trial
Singapore	49653	⤷ Try a Trial
Mexico	9202970	⤷ Try a Trial
Japan	H02501113	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.